Immix Biopharma, Inc.
SEC CIK 1873835 · IMMX · last insider filing 2026-05-29
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Chang Nancy T | Director | filed 2025 - 2026 |
| Buchan Melissa Jane | Director | filed 2021 - 2026 |
| Adams Helen C. | Director | filed 2021 - 2026 |
| Marquet Magda | Director | filed 2021 - 2026 |
| Rachman Ilya M | Director · CEO and Chairman | filed 2021 - 2026 |
| Ng Carey | Director | filed 2021 - 2026 |
| Morris Gabriel S | Director · Chief Financial Officer | filed 2021 - 2026 |
| Hsu Jason | Director | filed 2021 - 2026 |
| Chudnovsky Yekaterina | Director | filed 2023 - 2026 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Torchilin Vladimir P | Scientific Co-Founder | filed 2021 - 2021 |
| Ross Graham | CMO & Head of Clinical Dev. | filed 2021 - 2021 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.